PedAM

Pediatric Disease Annotations & Medicines

Disease	bronchitis
Phenotype	C0024115\|pulmonary disease
Sentences	15
PubMedID- 23865594	In the post-hib vaccine era, non-typeable h. influenzae (nthi) continue to cause infections of the respiratory tree including otitis media (om), conjunctivitis, sinusitis, pneumonia, and bronchitis especially in patients with chronic obstructive pulmonary disease (copd); as well as playing a role in early colonization of the lower respiratory tracts of children with cystic fibrosis [23,24].
PubMedID- 25909327	The second generation pde4-inhibitor roflumilast is the first oral obtainable pde4-inhibitor to treat chronic obstructive pulmonary disease (copd) associated with a chronic bronchitis and asthma [14,15].
PubMedID- 26528246	Impaired mucociliary clearance (mcc) is a hallmark of acquired chronic airway diseases like chronic bronchitis associated with chronic obstructive pulmonary disease (copd) and asthma.
PubMedID- 24152603	Objective: roflumilast is the first phosphodiesterase 4 (pde4) inhibitor approved for the treatment of chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and history of exacerbations.
PubMedID- 21735384	Objectives: to determine whether beta2-agonists improve acute bronchitis symptoms in patients with no underlying pulmonary disease.
PubMedID- 23605250	Nontypeable haemophilus influenzae (nthi) is an opportunistic pathogen and a common cause of otitis media in children, chronic bronchitis, and pneumonia in patients with chronic obstructive pulmonary disease.
PubMedID- 22284994	Background: roflumilast is a newly approved phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of exacerbations.
PubMedID- 20689641	The revised indication for roflumilast is for the “maintenance treatment of chronic obstructive pulmonary disease (copd) associated with chronic bronchitis in patients at risk of exacerbations” and is more restrictive than broad maintenance treatment of copd (www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ucm207377.pdf).
PubMedID- 23152680	Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population.
PubMedID- 20723142	Chronic obstructive pulmonary disease in the absence of chronic bronchitis in china.
PubMedID- 22723325	Context: the phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of frequent exacerbations.
PubMedID- 23392624	Objective: to estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (laba) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis with a history of frequent exacerbations from the uk payer perspective.
PubMedID- 23768858	Background and objective: roflumilast is a recently marketed drug, indicated for maintenance treatment of severe chronic obstructive pulmonary disease associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.
PubMedID- 22029856	Roflumilast is a potent and targeted pde4 inhibitor, approved by the european commission as an add-on to bronchodilator therapy for the treatment of severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis in adults with a history of frequent exacerbations, and targets the underlying inflammation in copd.
PubMedID- 22768130	Individuals with smoking-induced lung disease, and in particular those with chronic obstructive pulmonary disease (copd) associated with chronic bronchitis [3], [4], exhibit pathologic features similar to cf, including mucus stasis and accumulation [4], [5], [6].

Page: 1